

Table 8.6c
Immunosuppression Use for Induction by Steroid Use at Discharge, 2004 to 2008
Recipients with Kidney-Pancreas Transplants

| | No Steroids Used for Maintenance | | Steroids Used for Maintenance | |
|---|----------------------------------|--------|-------------------------------|--------|
| | N | % | N | % |
| Functioning Graft with Immunosuppression Info at Discharge | 1,298 | 100.0% | 2,969 | 100.0% |
| Induction Drugs | | | | |
| Atgam/NRATG/NRATS | 19 | 1.5% | 56 | 1.9% |
| OKT3 | 1 | 0.1% | 17 | 0.6% |
| Thymoglobulin | 810 | 62.4% | 1,485 | 50.0% |
| Zenapax | 8 | 0.6% | 222 | 7.5% |
| Simulect | 38 | 2.9% | 302 | 10.2% |
| Campath | 307 | 23.7% | 271 | 9.1% |
| Rituximab | 10 | 0.8% | 6 | 0.2% |
| No Induction Drug Reported | 163 | 12.6% | 686 | 23.1% |

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Includes patients with a functioning graft at discharge.

Steroids used for induction are not counted.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.